The Latest Cardiac and Vascular News
JanOne’s lead drug clinical candidate TV1001SR to treat PAD and associated pain will be manufactured by CoreRX Pharma with phase 2b trials expected to begin Q4 2020 LAS VEGAS, Feb. 6, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs […]
Soin brings extensive pain treatment and clinical experience to the JanOne team with particular expertise in pain associated with cardiovascular conditions LAS VEGAS, Jan. 28, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ:JAN), a company focused on finding treatments for conditions that cause severe pain and bringing to market drugs and therapies with nonaddictive […]
Dr. Christopher Kevil, pioneer in nitrite based PAD treatment and Dr. Amol Soin, foremost expert is neuropathic pain, provide scientific insight on the pain relieving qualities of JanOne’s lead drug candidate Interview to be distributed nationally on all 193 Sinclair broadcasting network affiliate stations in 89 markets across the nation […]
Kevil brings global scientific expertise to advance JanOne’s drug development portfolio and advise on upcoming Phase 2b clinical trials for PAD LAS VEGAS, Jan. 16, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ:JAN) appoints Christopher Kevil, Ph.D., a pioneer in nitrite based PAD treatment, to lead its scientific advisory board. In this role, Dr. Kevil will […]
Phase 2b testing planned for PAD treatment and PAD-associated pain to address 8.5 million patient US market LAS VEGAS, Nov. 25, 2019 /PRNewswire/ — JanOne Inc. (NASDAQ: JAN), a company focused on reducing opioid addiction by finding treatments for conditions accompanied by pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties, […]
